[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338275931{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER RSU” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. EDVINS MIKLASEVICS” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”RIGA STRADINAS UNIVERSITY” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_empty_space height=”15px”][vc_single_image image=”140″ img_size=”medium” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”http://www.rsu.lv/eng/”][/vc_column][vc_column width=”2/3″][vc_column_text]

Riga Stradins University (RSU) is the largest university in Latvia. It derives from the Rīga Medical Institute and offers medicine and health care studies as well as dynamic social science studies. More than 8000 students are enrolled in University programmes and about 25% are from abroad. Within the University, the Medical Education Technology Centre offers local and international medical and healthcare students the opportunity to use advanced technological features in training and lecture rooms equipped with up-to- date simulator systems.

Edvīns Miklaševičs Ph.D. is Professor of Medical Genetics at Riga Stradiņš University and Director of Institute of Oncology. His Group is involved in study of risk factors for genetic susceptibility of cancer and prognostic – predictive tumour biomarkers. He is one of leading regional contributors in molecular epidemiology of heritable cancers. His group will collaborate in patients recruitment and genetic analysis.

[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”250″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]


1) Kalniete et al., High expression of mir-214 is associated with worse disease-specific survival of the triple-negative breast cancer patients. Hereditary Cancer in Clinical Practice 2015, 2015, 13:7.

2) Serrano-Fernandez et. al.,. Cumulative small effect genetic markers and the risk of colorectal cancer in Poland, Estonia, Lithuania and Latvia. Gastroenterology Res. Practice, 2015, Article ID 204089.

3) Dymerska et al., Lynch syndrome mutations shared by the Baltic States and Poland. Clin. Genet., 2014, 86, 190 – 193.

4) Berzina et. al., BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families. BMC Med. Genet.
2013, 14:61.

5) Plakhins et. al., Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients. Fam. Cancer 2013, 12, 683 – 689.